Janux Therapeutics amasses $56m Series A

Janux Therapeutics, a developer of immunotherapies, has secured $56 million in Series A financing.

Janux Therapeutics, a developer of immunotherapies, has secured $56 million in Series A financing. Avalon Ventures led the round with participation from other backers that included OrbiMed, RA Capital Management, Bregua and Correlation Ventures.

Source: Press Release